Ajovy

Active Ingredient(s): Fremanezumab-vfrm
FDA Approved: * September 14, 2018
Pharm Company: * TEVA PHARMS USA
Category: Migraine / Tension Headache

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Ajovy Overview

Fremanezumab (INN) is a humanized monoclonal antibody directed against calcitonin-related polypeptides (CGRP) alpha and beta.[1] It was originated by Rinat Neuroscience Corporation, which licensed it to Teva.[2] In 2018 Teva stopped development of fremanezumab for the treatment of chronic cluster headache after the primary endpoint of a Phase III trial was not met; Teva was still developing it for episodic cluster headache and migraine.[3] Se...

Read more Ajovy Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Fremanezumab

Recent Ajovy Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Fremanezumab-vfrm
  • Injection: 150mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Ajovy: (1 result)

Sorted by National Drug Code
  • 51759-204 Ajovy 225 mg/1.5ml Subcutaneous Injection by Teva Pharmaceuticals USA, Inc.

Other drugs which contain Fremanezumab-vfrm or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 15 October 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 501 S. Cherry St, Suite 1100, Denver, CO, 80246, USA